Cargando…

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Objective: Bone marrow fibrosis is the second most common complication that causes morbidity and mortality inpatients with Philadelphia-negative myeloproliferative neoplasms (MPNs). The aim of this study was to investigate theassociation between JAK2V617F mutation and bone marrow fibrosis at diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales: Arı, M. Cem, Büyüktaş, Deram, Eşkazan, A. Emre, Öngören Aydın, Şeniz, Tanrıkulu, Eda, Başlar, Zafer, Buyru, A. Nur, Ferhanoğlu, Burhan, Aydın, Yıldız, Tüzüner, Nükhet, Soysal, Teoman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986748/
https://www.ncbi.nlm.nih.gov/pubmed/24744667
http://dx.doi.org/10.5505/tjh.2012.58751
Descripción
Sumario:Objective: Bone marrow fibrosis is the second most common complication that causes morbidity and mortality inpatients with Philadelphia-negative myeloproliferative neoplasms (MPNs). The aim of this study was to investigate theassociation between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with MPNs. Material and Methods: In total, 149 patients with MPNs were retrospectively evaluated to determine if there was anassociation between the histological grade of bone marrow fibrosis and JAK2V617F mutation. Results: In all, 67.7% of the patients carried the mutated JAK2 gene. The presence of JAK2V617F mutation was notassociated with the occurrence of bone marrow fibrosis (P=0.55) or its grade at diagnosis (P=0.65). Conclusion: Molecular mechanisms or genetic defects other than JAK2V617F may underlie the occurrence of bonemarrow fibrosis in patients with MPNs.